Chemotherapy without acute leukemia as secondary diagnosis with cc DRG 847

by

The 2024 Diagnosis Related Groups dataset

DRG 847

Chemotherapy without acute leukemia as secondary diagnosis with cc

Z08  Encounter for follow-up examination after completed treatment for malignant neoplasm

  • Z08 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
  • Short description: Encntr for follow-up exam after trtmt for malignant neoplasm
  • The 2024 edition of ICD-10-CM Z08 became effective on October 1, 2023.
  • This is the American ICD-10-CM version of Z08 – other international versions of ICD-10 Z08 may differ.

Applicable To

  • Medical surveillance following completed treatment

Use Additional

  • code to identify any acquired absence of organs (Z90.-)

Type 1 Excludes

  • aftercare following medical care (Z43–Z49, Z51)

The following code(s) above Z08 contain annotation back-references

 that may be applicable to Z08:

  • Z00-Z99  Factors influencing health status and contact with health services
  • Z00-Z13  Persons encountering health services for examinations

Approximate Synonyms

  • Follow up exam after cancer treatment completion
  • Follow up exam after completion of cancer treatment done
  • Vaginal pap, had hysterectomy for cancer
  • Vaginal papanicolaou smear with history of hysterectomy for cancer done

Present On Admission

  • Z08 is considered exempt from POA reporting.

ICD-10-CM Z08 is grouped within Diagnostic Related Group(s) (MS-DRG v41.0):

  • 826 Myeloproliferative disorders or poorly differentiated neoplasms with major o.r. Procedures with mcc
  • 827 Myeloproliferative disorders or poorly differentiated neoplasms with major o.r. Procedures with cc
  • 828 Myeloproliferative disorders or poorly differentiated neoplasms with major o.r. Procedures without cc/mcc
  • 829 Myeloproliferative disorders or poorly differentiated neoplasms with other procedures with cc/mcc
  • 830 Myeloproliferative disorders or poorly differentiated neoplasms with other procedures without cc/mcc
  • 837 Chemotherapy with acute leukemia as secondary diagnosis or with high dose chemotherapy agent with mcc
  • 838 Chemotherapy with acute leukemia as secondary diagnosis with cc or high dose chemotherapy agent
  • 839 Chemotherapy with acute leukemia as secondary diagnosis without cc/mcc
  • 846 Chemotherapy without acute leukemia as secondary diagnosis with mcc
  • 847 Chemotherapy without acute leukemia as secondary diagnosis with cc
  • 848 Chemotherapy without acute leukemia as secondary diagnosis without cc/mcc

Convert Z08 to ICD-9-CMCode History

  • 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
  • 2017 (effective 10/1/2016): No change
  • 2018 (effective 10/1/2017): No change
  • 2019 (effective 10/1/2018): No change
  • 2020 (effective 10/1/2019): No change
  • 2021 (effective 10/1/2020): No change
  • 2022 (effective 10/1/2021): No change
  • 2023 (effective 10/1/2022): No change
  • 2024 (effective 10/1/2023): No change

Code annotations containing back-references to Z08:

Diagnosis Index entries containing back-references to Z08:

Z51.11  Encounter for antineoplastic chemotherapy

  • Z51.11 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
  • The 2024 edition of ICD-10-CM Z51.11 became effective on October 1, 2023.
  • This is the American ICD-10-CM version of Z51.11 – other international versions of ICD-10 Z51.11 may differ.

The following code(s) above Z51.11 contain annotation back-references

 that may be applicable to Z51.11:

  • Z00-Z99  Factors influencing health status and contact with health services
  • Z40-Z53  Encounters for other specific health care
  • Z51  Encounter for other aftercare and medical care
  • Z51.1  Encounter for antineoplastic chemotherapy and immunotherapy

Approximate Synonyms

  • Cancer chemotherapy
  • Chemotherapy
  • Chemotherapy done
  • Chemotherapy for neoplasm done

Present On Admission

  • Z51.11 is considered exempt from POA reporting.

ICD-10-CM Z51.11 is grouped within Diagnostic Related Group(s) (MS-DRG v41.0):

  • 826 Myeloproliferative disorders or poorly differentiated neoplasms with major o.r. Procedures with mcc
  • 827 Myeloproliferative disorders or poorly differentiated neoplasms with major o.r. Procedures with cc
  • 828 Myeloproliferative disorders or poorly differentiated neoplasms with major o.r. Procedures without cc/mcc
  • 829 Myeloproliferative disorders or poorly differentiated neoplasms with other procedures with cc/mcc
  • 830 Myeloproliferative disorders or poorly differentiated neoplasms with other procedures without cc/mcc
  • 837 Chemotherapy with acute leukemia as secondary diagnosis or with high dose chemotherapy agent with mcc
  • 838 Chemotherapy with acute leukemia as secondary diagnosis with cc or high dose chemotherapy agent
  • 839 Chemotherapy with acute leukemia as secondary diagnosis without cc/mcc
  • 846 Chemotherapy without acute leukemia as secondary diagnosis with mcc
  • 847 Chemotherapy without acute leukemia as secondary diagnosis with cc
  • 848 Chemotherapy without acute leukemia as secondary diagnosis without cc/mcc

Convert Z51.11 to ICD-9-CMCode History

  • 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
  • 2017 (effective 10/1/2016): No change
  • 2018 (effective 10/1/2017): No change
  • 2019 (effective 10/1/2018): No change
  • 2020 (effective 10/1/2019): No change
  • 2021 (effective 10/1/2020): No change
  • 2022 (effective 10/1/2021): No change
  • 2023 (effective 10/1/2022): No change
  • 2024 (effective 10/1/2023): No change

Diagnosis Index entries containing back-references to Z51.11:

  • Chemotherapy (session) (for)
    • cancer Z51.11
    • neoplasm Z51.11
  • Encounter (with health service) (for) Z76.89
    • chemotherapy for neoplasm Z51.11
  • Maintenance (encounter for)
    • antineoplastic chemotherapy Z51.11

Z51.12  Encounter for antineoplastic immunotherapy

  • Z51.12 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
  • The 2024 edition of ICD-10-CM Z51.12 became effective on October 1, 2023.
  • This is the American ICD-10-CM version of Z51.12 – other international versions of ICD-10 Z51.12 may differ.

The following code(s) above Z51.12 contain annotation back-references

 that may be applicable to Z51.12:

  • Z00-Z99  Factors influencing health status and contact with health services
  • Z40-Z53  Encounters for other specific health care
  • Z51  Encounter for other aftercare and medical care
  • Z51.1  Encounter for antineoplastic chemotherapy and immunotherapy

Present On Admission

  • Z51.12 is considered exempt from POA reporting.

ICD-10-CM Z51.12 is grouped within Diagnostic Related Group(s) (MS-DRG v41.0):

  • 826 Myeloproliferative disorders or poorly differentiated neoplasms with major o.r. Procedures with mcc
  • 827 Myeloproliferative disorders or poorly differentiated neoplasms with major o.r. Procedures with cc
  • 828 Myeloproliferative disorders or poorly differentiated neoplasms with major o.r. Procedures without cc/mcc
  • 829 Myeloproliferative disorders or poorly differentiated neoplasms with other procedures with cc/mcc
  • 830 Myeloproliferative disorders or poorly differentiated neoplasms with other procedures without cc/mcc
  • 837 Chemotherapy with acute leukemia as secondary diagnosis or with high dose chemotherapy agent with mcc
  • 838 Chemotherapy with acute leukemia as secondary diagnosis with cc or high dose chemotherapy agent
  • 839 Chemotherapy with acute leukemia as secondary diagnosis without cc/mcc
  • 846 Chemotherapy without acute leukemia as secondary diagnosis with mcc
  • 847 Chemotherapy without acute leukemia as secondary diagnosis with cc
  • 848 Chemotherapy without acute leukemia as secondary diagnosis without cc/mcc

Convert Z51.12 to ICD-9-CMCode History

  • 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
  • 2017 (effective 10/1/2016): No change
  • 2018 (effective 10/1/2017): No change
  • 2019 (effective 10/1/2018): No change
  • 2020 (effective 10/1/2019): No change
  • 2021 (effective 10/1/2020): No change
  • 2022 (effective 10/1/2021): No change
  • 2023 (effective 10/1/2022): No change
  • 2024 (effective 10/1/2023): No change

Diagnosis Index entries containing back-references to Z51.12:

Leave a Comment